75
Participants
Start Date
January 25, 2024
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
CTI-1601
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Hospital of the University of Pennsylvania, Philadelphia
Fixel Institute for Neurological Disease, University of Florida Health, Gainesville
Morsani Center for Advanced Health Care, University of South Florida Health, Tampa
Ohio State University United States, Columbus
University of Iowa, Iowa City
University of California Los Angeles, Los Angeles
Clinilabs Drug Development, Corp., Eatontown
Lead Sponsor
Larimar Therapeutics, Inc.
INDUSTRY